Marlborough medical device company CardioFocus has secured $5 million in debt financing to move a U.S. trial forward and expand its commercialization efforts in Europe.
The company’s endoscopic ablation system is designed to help doctors visualize cardiac anatomy and perform trans-catheter procedures to treat atrial fibrillation.
The funding comes from Silicon Valley Bank of California, where CardioFocus has been a long-time client.
